1. ICH E9: Statistical principles for clinical trials. Int Conf Harmonization Tech Requirements Hum Use. 1998, [ http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000429.jsp ],
2. Ivanova A, Bolognese J, Perevozskaya I: Adaptive dose finding based on t-statistic for dose-response trials. Stat Med. 2008, 27: 1581-1592.
3. Berry DA, Müller P, Grieve AP, Smith M, Parke T, Blazek R, Mitchard N, Krams M: Adaptive Bayesian designs for dose-ranging drug trials.Case Studies in Bayesian Statistics. Volume V. Edited by: West M, Gatsonis C, Kass RE, Carlin B, Carriquiry A, Gelman A, Verdinelli I, West M. 2001, New York: Springer, 99-181.
4. Korn EL: Nontoxicity endpoints in phase I trial designs for targeted, non-cytotoxic agents. J Nat Cancer Inst. 2004, 96: 977-978.
5. Hunsberger S, Rubinstein LV, Dancey J, Korn EL: Dose escalation trial designs based on a molecularly targeted endpoint. Stat Med. 2005, 24: 2171-2181.